semaglutide and cardiac risk Oral Cardiovascular Outcomes in Type 2 Diabetes Insights into semaglutide cardiovascular research:

The Phase 3 clinical trial found that Wegovy reduced inflammation and scarring in people with metabolic dysfunction-associated steatohepatitis, or MASH.

The Pharmacists Defence Association (PDA) has said prescribers should not feel pushed toward any specific medicine or dose, following UK approval of a 7.2mg dose of Wegovy (semaglutide

Gastric ultrasound identifies increased residual gastric contents in patients on GLP-1 receptor agonists, showing that shorter drug withholding and fasting times are linked to higher aspiration risk before anesthesia.

Berberine - Thorne Berberine is a well-researched botanical that has been tested in numerous clinical studies

Explore the impact of GLP-1 receptor agonists on cardiometabolic health and their role in managing related conditions.

Combined SGLT2 inhibitor and GLP-1 receptor agonist therapy could provide additional cardiovascular and renal benefits for adults with type 2 diabetes, according to data from a meta-analysis published in The Lancet Diabetes &amp